The centre for disease control and prevention (CDC) of the Chinese city of Jiaxin said in a social media statement that two doses of Chinese vaccine manufacturer Sinovac Biotech's experimental COVID-19 vaccine, CoronaVac, will cost USD29.75 per dose and that vaccinations for key groups, including medical professionals, have begun.
Chinese authorities have to date not released pricing details for potential COVID-19 vaccines. However, hundreds of thousands of people have been given experimental vaccines in late-stage trials as part of an emergency inoculation programme launched in July 2020.
According to Reuters, it was not clear if Jiaxin city's pricing includes subsidies.
Sinovac's vaccine is in late stage trials in Brazil, Indonesia and Turkey and the company has said that an interim analysis of Phase 3 trial data could come as early as November 2020.
Reportedly, Bio Farma, a state-owned firm in Indonesia which has reached a deal for at least 40 million doses from Sinovac, has said that the vaccine will cost around USD13.60 per dose when it becomes available in the country.
China has said that while reasonable profits for companies are permitted, COVID-19 vaccines should be priced close to cost, Reuters added.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study